Baymatob key facts
as of Oct 2026- Developer of an AI-guided medical equipment designed to improve health outcomes for mothers and their babies.
- Baymatob is valued at approximately $5.4M as of Oct 2026 (last reported valuation).
- It has raised $4.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include ANDHealth, Edale Capital, Albert Impact Ventures, Australian Unity, Brandon Biocatalyst — 11 tracked in total.
- Status: Privately Held (backing).
Baymatob's last reported valuation, Mar 2024. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Baymatob: the Monday email on marks, rounds and moves
Baymatob funding rounds
No funding rounds for Baymatob are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Baymatob
11+Baymatob valuation
Baymatob's last reported valuation was $5.4 million in Mar 2024. No priced round, secondary trade or fund mark has surfaced since.
Baymatob investors
11 investors are on record for Baymatob, including ANDHealth, Edale Capital, Albert Impact Ventures and Australian Unity.
About Baymatob
Developer of an AI-guided medical equipment designed to improve health outcomes for mothers and their babies. The company's product demonstrates the ability to identify women who are at higher risk of developing postpartum hemorrhage before they give birth and predicts clinical actions to prevent the leading cause of preventable maternal death, enabling healthcare providers to acquire, interpret, and predict critical information on pregnancy progression and risks to mothers and their babies.
- Sector
- Healthcare
- HQ
- Leichhardt, Australia
- Founded
- 2013
- Employees
- 20
- Website
- baymatob.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.